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Background/aim: Vaccines are often lyophilized in order to retain their stability and efficacy for a longer period of time. However, the
same lyophilization process may also cause a major degradation of the vaccine, especially during early phases of manufacturing, leading
to a loss of potency of the product. Many viral diseases, such as rabies, are acute and fatal unless the vaccine is administered prior to
exposure or the onset of symptoms in the case of postexposure treatment.
Materials and methods: We investigated the effect of lyophilization on the stability of the virus structure during rabies vaccine
manufacturing using dynamic light scattering and transmission electron microscopy.
Results: Our results indicate that some viruses lose their stability and efficacy in the course of lyophilization if the pH of the cell culture
medium is controlled by solvated CO2 because the structure of the rabies virus is very sensitive to the solution pH: the virus either
aggregates or its shape is deformed at low solution pH, whereas at high pH empty capsid shells are formed.
Conclusion: Based on our findings, we developed a new formulation for the rabies vaccine that is stable in different buffers owing to the
prevention of pH upshift upon lyophilization.
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1. Introduction
Rabies is an acute and almost always lethal viral encephalitis
affecting only mammals (1) and is one of the major causes
of death in many parts of the developing world, killing
more than 55,000 individuals, mostly children, each year
(2). Some of the reasons for this high death toll are lack of
an effective vaccine that works under conditions found in
these parts of the world and affordability, which obviates
multiple dose administrations.
Rabies is caused by the rabies virus, which belongs
to the genus Lyssavirus of the family Rhabdoviridae that
contains about 80 viruses, often characterized by their
bullet shape (3). The rabies virus is approximately 200
nm in length and has a diameter of 80–100 nm (Figure
1). It has nonsegmented, single-stranded, negative-sense
genomic RNA (~12 kb) that encodes five proteins (4–11).
The RNA is linked with about 1800 nucleoproteins that are
tightly bound to a nucleocapsid (12). The matrix proteins
combine with lipids to form an envelope surrounding this
nucleocapsid.
In order to immunize a person against rabies, it is
believed that the structure of the virus is required to
* Correspondence: veysel.kayser@sydney.edu.au

remain intact during administration. Currently, there
are three human rabies vaccines: the human diploid
cell vaccine (SP), rabies vaccine adsorbed (RVA), and
purified chick embryo cell culture vaccine (PCECV) (13).
SP was approved in 1980 in the United States and since
then it has been widely used globally for general pre- and
postexposure immunization of humans (14). Previous
vaccines caused adverse side effects and were extremely
painful, and in addition they were not 100% effective
in preventing fatal infection. In contrast, the SP vaccine
provided a rapid immune response with less pain and
fewer side effects, required fewer doses, was more effective
in preventing infection, and thus was considered to be an
advanced vaccine compared to previously offered duck
embryo vaccines. Both the liquid form and lyophilized
versions are available. SP in its lyophilized form is usually
stable and its potency is generally retained for a long time
at typical storage temperatures of 2–8 °C (14). However,
the lyophilized form sometimes shows degradation
after lyophilization, attributed to the drying process. We
set out to investigate the reasons for this degradation
phenomenon.
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Assuring the stability of viral vaccines is imperative
(15,16) and several methods have been developed for this
daunting task. The most commonly used excipients for
stabilization of formulations are listed in the GRAS list.
In fact, this concern is also applicable for other additives
and preservatives used in biological drug formulations.
Another stabilization method is to lyophilize the vaccine
to slow down the degradation process. The major
problem with the lyophilization method is the potential
degradation of the product during or after the freezing
process. In practice, this process may require keeping the
virus concentration quite high, so that after lyophilization
some whole viruses that are capable of inducing immune
response would remain in the vial even if degradation
occurs.
The recent increase in awareness of the safety, product
constituents, and potential side effects of vaccines has
created a new challenge to develop more stable and
safe vaccine formulations. Rational drug formulation
requires mechanistic insight into molecular interactions,
understanding of the mechanism of degradation, and
understanding of the efficacy, stability, feasibility, and
performance of the vaccine in the host cell (14,17–19).
Unfortunately, currently we have a limited understanding
of the vaccine degradation process due to the complexity
of viral nature, particularly if structurally disintegrated
virus particles are involved. Consequently, the stabilization
of vaccines is frequently an empirical procedure
based on observed changes in their biological activity.
Design of experiments, rational design, and orthogonal
characterization tools allow supplementing empirical
knowledge for the development of new formulations.
Nevertheless, in order to avoid degradation of viral
vaccines, understanding the underlying mechanism of
degradation phenomena at the molecular level is necessary.
The liquid rabies vaccine SP formulation is an industry
standard and a relatively well-established formulation.
However, since it is produced with a human cell line, it is not
purified, and therefore it contains many nonviral proteins
and is susceptible to degradation upon lyophilization. The
degradation cannot be detected with a standard ELISA
test during quality control after lyophilization, but the
lyophilized vaccine fails the NIH test (20).
Presently, knowledge concerning the stability of the
rabies virus is relatively limited. Nonetheless, it is known
that above 56 °C it has thermolability (21), and that
recurring freeze-thaw cycles cause capsid degradation,
presumably due to virus disassembly. Below pH 6 its activity
drastically decreases due to a conformational change of
its glycoprotein G. Divalent cations such as calcium and
magnesium tend to stabilize the virus. Reports regarding
variation of solution conditions and lyophilization are
limited. Although various conditions perturbing the
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stability of the rabies virus have been described briefly
(14,18,22–24), the underlying mechanism of degradation
is not yet understood, as is often the case for viruses.
In order to understand degradation and therefore be
able to better take steps to avoid it, we have performed a
comparative study of lyophilized and nonlyophilized virus
samples that fail the NIH test. We hypothesized that the
pH change causes vaccine degradation upon lyophilization
by structurally disintegrating virus particles. To test our
hypothesis and to determine the reasons for vaccine
destruction after lyophilization, we have conducted
experiments with three formulations (liquid SP (SP1),
lyophilized SP (lyo SP1), and control SP (SP2)) of the rabies
vaccine with dynamic light scattering (DLS), transmission
electron microscopy (TEM), and optical microscope.
DLS and TEM data were correlated in a combinatorial
manner in this manuscript. TEM provides both size and
shape information on the sample, but only a small fraction
of the sample is imaged. There is also a possibility of
inducing a large aggregate formation under the vacuum.
DLS, on the other hand, requires liquid samples and can
be applied to a bulk sample; however, it depends on the
model used. Therefore, both methods were correlated to
obtain information about the size, shape, and number
of particles in vaccines. The SP2 sample was used as the
control because it is a purified and reformulated virus and
does not degrade noticeably upon lyophilization. Here we
show that the structural integrity of the virus particles,
and hence in turn vaccine degradation, can be prevented
by controlling the solution pH by an alkali at pH 8 during
lyophilization. To demonstrate the influence of solution
conditions on virus stability, we have lyophilized the virus
under different solution conditions such as various buffer
types (Tris, PBS, and potassium phosphate). We also show
that the shape of the virus structure changes with solution
pH, and the degradation mechanism varies depending on
whether solution pH is high or low: at high pH, the virus
displays only empty capsids, whereas at low pH it splits
and aggregates.
2. Materials and methods
All vaccines were received from Sanofi-Pasteur in liquid
or lyophilized forms. The manufacturing processes and
specifications were identical to clinical batches. The
inactivation of the virus was done by β-propiolactone.
Lyophilization of vaccine samples was done with the
same procedure as in the clinical batches in SanofiPasteur facilities. Lyophilization of new formulations
was performed with home-built equipment at MIT that
included a pump, a vacuum chamber, and a thermostat.
All chemicals were purchased from Sigma-Aldrich (St.
Louis, MO, USA) and used as received without further
purification. Dialysis tubes (FLT CE 3 ML Spectra/Por
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Float-A-Lyzer with 50 kDa) were obtained from VWR
(Radnor, PA, USA) for buffer exchange experiments.
All experiments were repeated at least three times, and
all control studies were conducted where necessary.
Furthermore, the background was subtracted from the
spectroscopic signals as appropriate. The results have been
obtained with controls at similar concentrations to assess
the impact of formulation changes.
2.1. Dynamic light scattering experiments
We used the Wyatt DynaPro Titan DLS instrument
(Santa Barbara, CA, USA) for the DLS experiments.
Experiments were conducted with a micro quartz cuvette
at room temperature with a volume of 100 µL. Results are
reported using the Rayleigh Spheres model. We also tried
the Coils and Isotropic Spheres models, but found that
there was no considerable difference between the results
with these models and those using the Rayleigh Spheres
model. For each sample, the DLS equipment measures the
scattered light for 10 s and repeats the process 10 times.
Independently, each DLS experiment was repeated three
times with three different sample sets, and the average was
taken. DLS data were transferred to data plotting software
(Igor Pro) as an ASCI file and replotted as original to
display as a higher quality image.
2.2. Transmission electron microscope experiments
Imaging was done using the FEI Tecnai Spirit equipped
with an AMT digital camera (Eugene, OR, USA). The
samples were negatively stained using 2% uranyl acetate
(UA), 2% ammonium molybdate (AM), or 1% sodium
phosphotungstate (PTA). We found that imaging of
the viral structural detail was heavily dependent on the
negative staining method; PTA and AM gave better results
and higher resolution than UA.
2.3. Fluorescence microscope experiments
We used a Nikon Inverted TE300 optical microscope
to detect the virus with fluorescein isothiocyanate dyelabeled antirabies monoclonal antibody from Fujirebio
Diagnostics, Inc. (Malvern, PA, USA). The virus
formulation was dried on a microscope slide and antibody
solution was added, and then the slide was washed
several times with PBS to remove the unbound antibody
prior to recording images. Various virus and antibody
concentrations were checked. The best images were
obtained with undiluted virus and 10× antibody dilution.
Standard fluorescein filters were used for both excitation
and emission paths.
3. Results and discussion
3.1. Rabies virus structure
Figure 1 shows the structure of the rabies virus by a TEM
experiment, where the surface glycoprotein layer as well
as capsid proteins can be seen due to enhanced resolution.

The unstressed but inactivated rabies virus in the control
vaccine (SP2) resembles the native virus as it appears in
the literature in size and shape, with about 80–100 nm
diameter and 100–200 nm length (Figure 1).
3.2. Effect of lyophilization on viral structure in a pH
controlled solution
DLS experiments give valuable information about the
size distribution of molecules in formulations and size
inhomogeneity of the samples. We conducted DLS
experiments to determine the inhomogeneity of the
samples (Figure 2). The DLS results showed that the
unstressed virus in the control sample (SP2) has one peak
corresponding to a single undegraded virus population,
with a diameter of about 100 nm (Figure 2A). The
SP formulation, on the other hand, has two different
populations (Figure 2B): the peak centered at 200 nm
corresponds to undegraded viruses, while the peak at 10
nm corresponds to remaining proteins from culture cells
with diameter of less than 10 nm. When SP1 is lyophilized,
the virus population is reduced drastically, the virus peak
in DLS experiments almost disappears, and larger as
well as smaller particles are observed (Figure 2C). The
species that have smaller sizes than the whole virus are
probably disassembled viruses, and the larger particles are
aggregated viruses and proteins.
Although there are very little published data on the
rabies virus structure and stability, it was reported that the
rabies virus has a typical “bullet” shape (25,26). We have
found that the observed shape of the virus depends heavily
on the method used for negative staining in the TEM
experiments. In particular, PTA or AM staining methods
were superior to that of UA, which is in agreement with
the observations of others (26).
Contrary to TEM, optical microscopy can detect
degraded viruses in large-sized clusters that probably
contain both viral and protein aggregates. Figure 3 shows
the fluorescence of the dye-labeled antirabies antibody.
The sample shown in Figure 3A contains the virus sample
only, Figure 3B the original liquid sample, and Figure 3C
the lyophilized sample. It is expected that each virus would
have multiple bound antibodies giving rise to an enhanced
detectable signal, assuming that antibody fluorescence can
be directly linked to the number of viruses per volume
in the sample. The most striking differences between
samples are concentration dependencies. Our analysis
with the optical microscope indicates the existence of
aggregates (large clusters) in the lyophilized sample and
shows that the concentration of the whole virus is reduced
significantly after lyophilization (Figure 3C).
The solution pH of the SP1 formulation increases by
about 1–1.5 pH units due to lyophilization from pH 8 to
pH 9.6, as shown in the Table. The labile buffer system is
removed during sublimation and thus the virus is exposed
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Figure 1. TEM image of the rabies virus from the SP2 sample. The sample was negatively stained with PTA. Scale bars are 100 nm.

Figure 2. DLS results of the rabies virus vaccine formulations. (A) SP2 sample, (B) SP1 sample, and (C) lyophilized SP1 sample,
reconstituted with distilled water.

to about 1–1.5 pH units after rehydration, whereas the
SP2 control formulation with higher virus concentration
in a different buffer does not show any pH change due to
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lyophilization. Figures 4–7 show that this pH upshift affects
the virus structure considerably. We hypothesize that this
sudden pH increase causes degradation of the rabies virus
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Figure 3. Optical microscope results of (A) SP2 sample, (B) liquid SP1 sample, and (C) lyophilized SP1 sample. Green color is due to the
fluorescent-labeled antirabies antibodies. Scale bar is 40 µm.

Table. Effect of lyophilization on solution pH.
pH
Before lyophilization

After lyophilization

SP2 formulation (control)

8.1

8.1

SP1 formulation

8.5

9.4

Lyophilized SP1 sample after reconstitution with distilled water

-

9.6

Figure 4. DLS results showing the effect of pH on the SP1 vaccine. (A) SP1 formulation. (B) When the solution pH of SP1 was increased
to pH 10.
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Figure 5. TEM images showing the overall effect of pH on viruses. At pH 4 large protein aggregates are observed. As the solution pH is
increased empty capsids are formed: at pH 10 there are some empty capsids, but at pH 12 only empty capsids are visible (all scale bars
are 500 nm). Arrows indicate some of the particles. Orange: empty capsids, blue: viruses, and red: protein aggregates.

Figure 6. TEM images showing the effect of pH on a single virus structure. At pH <7 the virus aggregates as well as disassembles, but at
pH >10 it gradually loses its protein layers and eventually only the capsid remains. The scale bars are 100 nm in each picture; “Formul”
is the formulation solution at around pH 8; inset images at pH 4 and pH 11 show other types of commonly observed structures.

structure. Hence, we have tested the dependence of the
virus structure on the solution pH and found that at high
pH values, the virus loses its surface protein layers and
adopts empty ring structures, probably consisting of the
capsid proteins (Figure 6). At low pH values, though, the
virus disassembles or aggregates (Figure 6).
The virus structure can be conserved as shown in Figure
7 by using different formulation buffers, or by keeping the
solution pH constant. Our method of keeping the solution
pH constant by other means than CO2, e.g., alkali, preserves
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the desired solution pH during lyophilization and this in
turn keeps the viral structure intact upon lyophilization.
3.3. Influence of CO2 on solution pH
As mentioned, the virus structure is extremely sensitive
to sudden pH changes. This is especially true in the SP1
formulations, where only a limited amount of virus is
available and the solution pH is controlled by CO2 during
the cell culture stage. Release of the labile buffer system
from the sample increases the solution pH, and thus the
virus structure is destroyed due to high pH. Dependence
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Figure 7. DLS results of the lyophilized SP1 sample using different buffers: (A) potassium phosphate buffer, (B) PBS buffer, and (C) Tris
buffer. Solution pH was controlled (pH 8) with alkali. The lyophilized virus was reconstituted with distilled water.

of the structure of the virus on solution pH is observed as
an enlarged virus in the DLS results (Figure 4), where the
virus diameter increases at high pH, forming empty virus
structures seen in the TEM results (Figure 5) and probably
containing only the virus capsids.
A certain amount of carbon dioxide (CO2) may be
dissolved in the buffer as long as the pressure is maintained
at a relatively constant level, and the pH of the solution
changes due to dissolved CO2. If the pressure drops
significantly in a short period of time, CO2 is expected to be
released from the environment. During the lyophilization
process, both the temperature and the pressure drop
drastically, and we believe that this process releases CO2
from the system, which in turn causes the pH upshift.
When CO2 is dissolved in water, it forms carbonic acid
(H2CO3, a weak acid), which in turn forms a bicarbonate
ion (HCO3–) and a hydronium cation (H3O+) after reacting
with water. Note that both CO2 and H2CO3 react slightly
and reversibly with water based on the following reactions:
CO2 + H2O ⇌ H2CO3
H2CO3 + H2O ⇌ HCO3– + H3O+
To circumvent this problem, we developed novel stable
formulations that have the same pH before and after
lyophilization, as discussed in the following section.
3.4. Stable formulation that does not degrade during
lyophilization
The stability of SP1 with pH fixed at 8 with NaOH (our
new formulation) was compared to the control sample
SP2 and to the lyophilized SP1 whose pH during the
cell culture process was controlled with dissolved CO2.
In order to prepare the new formulation, liquid SP1
samples were subjected to buffer exchange by dialysis for
48 h in 15 mM Tris, 15 mM potassium phosphate, or PBS
buffers, all at pH 8. Dialysis buffers were replaced with

freshly prepared buffers every 12 h. After the dialysis,
the samples were immediately frozen at –80 °C and
lyophilized, and subsequently the samples were analyzed
with DLS (Figure 7). In summary, our biophysical analyses
of the reformulated SP1 show an enhanced stability
upon lyophilization compared to the original lyophilized
sample. The strong correlation between solution pH and
structural stability of the virus is a proof-of-concept for
our methodology to stabilize the rabies vaccine. Recently
we reported the effect of a surfactant on the influenza virus
with observations akin to this study, albeit with different
excipients and conditions (27). Our current method allows
preparing the vaccine in many different buffers (e.g., Tris
or potassium phosphate) and can also be applied in other
lyophilized vaccines or therapeutic protein formulations
where pH is controlled by CO2 or other methods in the
liquid form but is possible to be shifted upon lyophilization.
To conclude, we have studied the mechanism of the
rabies virus disassembly at various solution pH, different
buffers, and elevated temperature conditions. We have
verified our hypothesis that during lyophilization the
vaccine degrades due to destruction of the viral structure.
This destruction is caused by an increase of the solution
pH during lyophilization and/or upon reconstitution. This
pH upshift is due to the substantial loss of dissolved CO2 in
the labile buffer system that is used to control the solution
pH in cell culture medium 199. Since the virus structure
is marginally stable in a narrow pH range in solution, the
upshift of solution pH during the lyophilization process
causes the virus to lose its structural integrity, thus
resulting in the observed degradation of the vaccine. We
have also conducted accelerated studies to determine the
effect of pH on the virus structure further. We showed that
the rabies virus in the reference sample (SP2 formulation)
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is more stable both at high and low pH conditions than
the virus in the SP1 formulation. In addition, we found
that the virus shape was dependent on the negative
staining method used in the TEM experiments. Lastly,
we have developed a new rabies vaccine formulation with
enhanced stability by keeping the solution pH constant
with NaOH at pH 8. We showed that the new formulation
is stable in various buffers including Tris, potassium
phosphate, and PBS after lyophilization as opposed to the
old rabies vaccine. The next step for our new formulation
will be a stability study as a function of solution pH. Our
methodology will be of great interest to the pharmaceutical
industry for improving vaccine formulations, especially
for labile bioproducts to meet strict stability guidelines. In
addition, formulations prepared with our approach could
contain much less virus, allowing more vaccines to be

manufactured with the same amount of virus produced.
The latter would have benefits for patients, such as fewer
side effects, since the formulation needs to contain a low
amount of biological material. It is also expected to cause
less pain associated with vaccine administration, since the
solution pH is closer to physiological pH.
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